Study guide

6.3 Anticoagulants, Antiplatelets & Hematology Agents

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

6.3 Anticoagulants, Antiplatelets & Hematology Agents

Key Takeaways Explain This Topic AI

Warfarin inhibits vitamin K epoxide reductase (VKORC1); the INR target is 2-3 for atrial fibrillation and venous thromboembolism and 2.5-3.5 for mechanical mitral valves

Reverse life-threatening bleeding on warfarin with four-factor prothrombin complex concentrate plus intravenous vitamin K; vitamin K alone suffices for high INR without bleeding

Enoxaparin and other low-molecular-weight heparins act predominantly against factor Xa, need dose reduction in renal impairment, and all heparins can cause heparin-induced thrombocytopenia

Dabigatran is reversed by idarucizumab and the anti-Xa DOACs (rivaroxaban, apixaban, edoxaban) by andexanet alfa; DOACs are contraindicated with mechanical heart valves

Prasugrel is contraindicated in patients with prior stroke or TIA, and clopidogrel is a CYP2C19-activated prodrug whose effect is blunted by omeprazole

Last updated: August 2026

Warfarin: The Vitamin K Antagonist

Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1) , blocking regeneration of reduced vitamin K and thereby the gamma-carboxylation of clotting factors II, VII, IX and X (and anticoagulant proteins C and S). Because factor II has a long half-life, full anticoagulation takes several days - which is why bridging with heparin or a low-molecular-weight heparin is used when rapid anticoagulation is needed and when warfarin is interrupted around surgery in high-risk patients.

Monitoring is by the international normalised ratio (INR) : target 2.0-3.0 for atrial fibrillation and venous thromboembolism, and 2.5-3.5 for mechanical heart valves (particularly mitral). Response varies with CYP2C9 and VKORC1 genetics , and with dietary vitamin K - advise patients to keep green leafy vegetable intake consistent , not absent. Major interactions that raise the INR include antibiotics (metronidazole, co-trimoxazole, macrolides, fluoroquinolones), amiodarone , azole antifungals and acute alcohol binges; enzyme inducers (rifampicin, carbamazepine, St John's wort) lower it. NSAIDs and antiplatelets add bleeding risk pharmacodynamically. For reversal: withhold warfarin and give oral/IV vitamin K for elevated INR without serious bleeding; for major or life-threatening bleeding use four-factor prothrombin complex concentrate (PCC) plus IV vitamin K, with fresh frozen plasma only if PCC is unavailable.

Heparin, LMWH and Fondaparinux

Unfractionated heparin (UFH) binds antithrombin and accelerates its inhibition of thrombin (IIa) and factor Xa; it is monitored by the aPTT and reversed by protamine sulfate . Low-molecular-weight heparins (LMWH) such as enoxaparin act predominantly against factor Xa , have predictable pharmacokinetics allowing fixed weight-based dosing without routine monitoring (anti-Xa levels only in pregnancy, obesity or renal failure), and require dose reduction in renal impairment (creatinine clearance below 30 mL/min). All heparins can cause heparin-induced thrombocytopenia (HIT) - an immune-mediated prothrombotic state with a falling platelet count, typically 5-10 days after starting. Management: stop all heparin immediately, never give warfarin alone during acute HIT (it can cause venous limb gangrene via protein C depletion), and anticoagulate with a non-heparin agent such as argatroban or fondaparinux . Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa via antithrombin; it is renally cleared and has a very low HIT risk.

Direct Oral Anticoagulants (DOACs)

Agent Target Key points Specific reversal

Dabigatran Thrombin (IIa) ~80% renally cleared - renal limits apply; dyspepsia common; capsules must not be opened Idarucizumab

Rivaroxaban Factor Xa 15 mg and 20 mg doses must be taken with food for absorption Andexanet alfa

Apixaban Factor Xa Favourable bleeding profile; dose-reduction criteria by age, weight, creatinine Andexanet alfa

Edoxaban Factor Xa Reduced efficacy if creatinine clearance is very high Andexanet alfa

DOAC advantages: fixed dosing with no routine coagulation monitoring and far fewer food interactions than warfarin. Limitations the exam tests: all are renally cleared to some degree (dabigatran most, so avoid in severe renal impairment); they are contraindicated with mechanical heart valves (the RE-ALIGN trial showed excess thrombosis with dabigatran) and should be avoided in triple-positive antiphospholipid syndrome , where warfarin remains standard. Strong CYP3A4/P-glycoprotein inhibitors and inducers alter levels of the anti-Xa agents.

Antiplatelet Agents

Aspirin irreversibly acetylates cyclo-oxygenase-1 (COX-1) , abolishing thromboxane A2 production for the platelet's 7-10 day lifespan; low doses (75-100 mg) are antiplatelet. Avoid in children (Reye's syndrome) and caution in asthma and peptic ulcer disease.

Clopidogrel is a prodrug activated by CYP2C19 that irreversibly blocks the platelet P2Y12 ADP receptor. Poor metabolisers gain little benefit, and omeprazole/esomeprazole blunt its activation - the classic interaction with acid-suppressing therapy.

Ticagrelor is a reversible P2Y12 antagonist needing no metabolic activation; characteristic adverse effects are dyspnea (usually transient) and ventricular pauses; it is a CYP3A4 substrate/inhibitor.

Prasugrel is the most potent thienopyridine but is contraindicated in patients with prior stroke or transient ischaemic attack because of intracranial bleeding risk, and is generally avoided over age 75 or under 60 kg body weight.

Anemia Therapy

Oral iron (ferrous sulfate, fumarate, gluconate) is first-line for iron-deficiency anemia: give on an empty stomach for best absorption (with food if gastrointestinal upset is intolerable), optionally with vitamin C to enhance uptake, and warn about black stools and constipation. Iron chelates tetracyclines and fluoroquinolones (separate by 2-4 hours), and its own absorption is reduced by PPIs, antacids, tea and dairy . Intravenous iron (iron sucrose, ferric carboxymaltose) is used for intolerance, malabsorption, inflammatory bowel disease or chronic kidney disease, with a small hypersensitivity risk.

Distinguish the macrocytic anemias: vitamin B12 deficiency causes macrocytosis plus neurological features (peripheral neuropathy, subacute combined degeneration of the cord), while folate deficiency does not. The critical rule: never give folic acid alone when B12 deficiency is possible - it corrects the anemia while neurological damage progresses silently. Treat with hydroxocobalamin first, or give both.

Finally, granulocyte colony-stimulating factor (G-CSF) - filgrastim, pegfilgrastim - stimulates neutrophil production and is used to prevent or treat chemotherapy-induced neutropenia ; its characteristic adverse effect is bone pain , and it is typically started 24-72 hours after chemotherapy.

Practical counselling closes the anticoagulation picture. Warfarin patients should take the dose at the same time each day, report any new prescription, over-the-counter product or herbal supplement before starting it, watch for bleeding signs (black stools, haematuria, prolonged nosebleeds, unusual bruising) and carry an anticoagulant alert card. Early in warfarin therapy there is a brief prothrombotic window because anticoagulant protein C falls before factor II - one more reason heparin bridging overlaps the first days of treatment. DOAC patients should be told that adherence matters even more than with warfarin because of the short half-lives: a missed dose leaves them unprotected within a day, and dabigatran capsules must be swallowed whole since opening them sharply increases bioavailability and bleeding risk.